Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation    CVM   US1508375086

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

CEL SCI : Adds Aintree University Hospital to Phase III Head and Neck Cancer Trial

04/16/2015 | 01:37am US/Eastern

CEL-SCI Corp. reported that Aintree University Hospital, in Liverpool, England, has become a clinical site for the Company's global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection).

This is the first center to join the Multikine Phase III study in the UK.

Aintree University Hospital is a large teaching hospital in Liverpool providing a range of acute and non-acute specialties. The hospital offers specialist services to a population of 1.5 million residents across the Northwest of England.

In a release, the Company noted that the Principal Investigator for the trial site is Professor Richard Shaw. He serves as Honorary Consultant in Oral & Maxillofacial / Head and Neck Surgery at Aintree University Hospital and is a surgeon specializing in head and neck cancers at the University of Liverpool.

"Dr. Shaw is a Key Opinion Leader in head and neck cancer who has participated in numerous trials exploring better ways to treat cancer. We are honored to have his participation and expertise in our trial." stated CEL-SCI Chief Executive Officer Geert Kersten.

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases.

More information:

((Comments on this story may be sent to

(c) 2015 ProQuest Information and Learning Company; All Rights Reserved., source Trade Publications

React to this article
04/16 CEL SCI : Adds Aintree University Hospital to Phase III Head and Neck Cancer Tri..
04/13 CEL SCI : NEW STORY UK's Aintree University Hospital Joins CEL-SCI's Phase III H..
04/13 CEL SCI : UK’s Aintree University Hospital Joins CEL-SCI’s Phase III..
04/02 CEL SCI : Other Events (form 8-K)
04/01 CEL SCI : NEW STORY CEL-SCI Reports 3rd Consecutive Month of Record Patient Enro..
04/01 CEL SCI : Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for..
03/18 CEL SCI : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form ..
03/12 CEL-SCI CORPORATION : Cel-Sci's Cancer Immunotherapy In Phase III Is Value Oppor..
03/09 CEL SCI : Secures Clearance to Conduct Phase III Trial in 21 Countries
03/06 CEL SCI : Updates on Patient Enrollment in 2015 for Its Phase III Head and Neck ..
Duration : Period :
CEL-SCI Corporation Technical Analysis Chart | CVM | US1508375086 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes